Revolution could have a first-line pancreatic balancing act
Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.
Astellas and Amgen join the pan-KRAS push
Astellas’s pan-KRAS degrader joins the company’s two clinical-stage G12D degraders.
Erasca enters its pan-RAS era
The company deprioritises its lead project, naporafenib, shifting to two Joyo-originated assets.
Another pan-KRAS project enters the clinic
Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.
A combination Revolution
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
Triple meeting 2024 – can Revolution succeed where others stumbled?
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
The Revolution is here, and it’s... confusing
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
Erasca doubles down on RAS
The young company’s eighth licensing deal brings in two RAS-targeting projects from Joyo.
